THERAPY DOSSIER · th-25d99d6289c6

FDI-6, a FOXM1-specific inhibitor (used as a loss-of-function challenge rather than a candidate therapeutic)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32938916 ↗2020Reported harm

Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing.

MouseWoundCD1 (streptozotocin-induced diabetes) and db/db miceMale and femalen = 13 diabetic foot ulcer patients; mouse n per group not stat…Topical application to the wound, covered with film dressing150 micromolar FDI-6Applied at the time of wounding

Model: Two 6 mm full-thickness excisional punch wounds on shaved dorsal skin. Diabetic models: streptozotocin 60 mg/kg intraperitoneally for 5 consecutive days with diabetes maintained 6 weeks before wounding, and db/db mice. Human arm: chronic diabetic foot ulcer wound-edge biopsies

Topical FDI-6 significantly inhibited wound healing versus vehicle at day 4 in non-diabetic mice and further delayed healing in streptozotocin diabetic mice, with reduced immune cell infiltrate and significantly fewer neutrophils and macrophages in both streptozotocin and db/db wounds. The harm is…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…